VenomAid Diagnostics
VenomAid Diagnostics create impact by providing affordable and rapid diagnosis for snakebite envenoming.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $800k Valuation: $5.0m | Seed | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (50 %) | 64 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 44 % | 35 % | (27 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
VenomAid is a pioneering company focused on revolutionizing snakebite care through advanced biotechnological methods. Operating in the healthcare and biotechnology market, VenomAid serves clinicians and healthcare providers who deal with snakebite incidents. The company combines state-of-the-art antibody discovery, venomics insights, and affordable diagnostic technologies to develop tools that empower clinicians in making informed decisions. VenomAid's business model revolves around the development and sale of affordable diagnostic tools that enhance the efficiency and accessibility of snakebite care. Revenue is generated through the sale of these diagnostic products to healthcare institutions and professionals. The company's mission is to reduce the global burden of snakebites by providing next-generation antivenoms and diagnostic tools, thereby making snakebite care more accessible, efficient, and life-saving.
Keywords: snakebite, diagnostics, antivenom, biotechnology, healthcare, antibody discovery, venomics, clinical tools, affordable technology, healthcare providers.